keyword
MENU ▼
Read by QxMD icon Read
search

Sarcomatoid Renal Cell Carcinoma

keyword
https://www.readbyqxmd.com/read/28736828/genomic-and-metabolic-characterization-of-a-chromophobe-renal-cell-carcinoma-cell-line-model-uok276
#1
Youfeng Yang, Cathy D Vocke, Christopher J Ricketts, Darmood Wei, Hesed M Padilla-Nash, Martin Lang, Carole Sourbier, J Keith Killian, Shawna L Boyle, Robert Worrell, Paul S Meltzer, Thomas Ried, Maria J Merino, Adam R Metwalli, W Marston Linehan
Chromophobe renal cell carcinoma (ChRCC) represents 5% of all RCC cases and frequently demonstrates multiple chromosomal losses and an indolent pattern of local growth, but can demonstrate aggressive features and resistance to treatment in a metastatic setting. Cell line models are an important tool for the investigation of tumor biology and therapeutic drug efficacy. Currently, there are few ChRCC-derived cell lines and none is well characterized. This study characterizes a novel ChRCC-derived cell line model, UOK276...
June 9, 2017: Genes, Chromosomes & Cancer
https://www.readbyqxmd.com/read/28731045/renal-cell-tumors-with-clear-cell-histology-and-intact-vhl-and-chromosome-3p-a-histological-review-of-tumors-from-the-cancer-genome-atlas-database
#2
Laura Favazza, Dhananjay A Chitale, Ravi Barod, Craig G Rogers, Shanker Kalyana-Sundaram, Nallasivam Palanisamy, Nilesh S Gupta, Sean R Williamson
Clear cell renal cell carcinoma is by far the most common form of kidney cancer; however, a number of histologically similar tumors are now recognized and considered distinct entities. The Cancer Genome Atlas published data set was queried (http://cbioportal.org) for clear cell renal cell carcinoma tumors lacking VHL gene mutation and chromosome 3p loss, for which whole-slide images were reviewed. Of the 418 tumors in the published Cancer Genome Atlas clear cell renal cell carcinoma database, 387 had VHL mutation, copy number loss for chromosome 3p, or both (93%)...
July 21, 2017: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/28725540/the-pathology-and-molecular-genetics-of-sarcomatoid-renal-cell-carcinoma-a-mini-review
#3
REVIEW
Shuanzeng Wei, Tahseen Al-Saleem
Sarcomatoid renal cell carcinoma is a highly aggressive tumor. It is not a distinct histologic entity as it can be found in any subtypes of renal cell carcinoma. Recent molecular and genetic evidence suggest that sarcomatoid component is transformed from a common progenitor of the associated renal cell carcinoma, and the TP53 gene plays a pivotal role in this process. The presence of sarcomatoid carcinoma indicates poor prognosis, which also correlates with the amount of the sarcomatoid component. Therefore, the presence and quantity of sarcomatoid component should be reflected in pathology reports...
2017: Journal of Kidney Cancer and VHL
https://www.readbyqxmd.com/read/28718911/clear-cell-renal-cell-carcinoma-validation-of-who-isup-grading
#4
Julien Dagher, Brett Delahunt, Nathalie Rioux-Leclercq, Lars Egevad, John R Srigley, Geoffrey Coughlin, Nigel Dunglinson, Troy Gianduzzo, Boon Kua, Greg Malone, Ben Martin, John Preston, Morgan Pokorny, Simon Wood, John Yaxley, Hemamali Samaratunga
AIM: In 2012, the International Society of Urological Pathology (ISUP) introduced a novel grading system for clear cell and papillary renal cell carcinoma (RCC) based upon increasing nucleolar prominence in grades 1 to 3, with the presence of extreme nuclear pleomorphism and/or tumour giant cells and/or sarcomatoid and/or rhabdoid differentiation as criteria for grade 4. This system is now incorporated in the latest World Health Organization renal tumour classification, being designated WHO/ISUP grading...
July 18, 2017: Histopathology
https://www.readbyqxmd.com/read/28716649/blood-platelet-volume-represents-a-novel-prognostic-factor-in-non-metastatic-renal-cell-carcinoma-patients-and-improves-the-predictive-ability-of-established-prognostic-scores
#5
Maximilian Seles, Florian Posch, Georg P Pichler, Thomas Gary, Karl Pummer, Richard Zigeuner, Georg C Hutterer, Martin Pichler
PURPOSE: The average size of blood platelets determined by the mean platelet volume (MPV), might represent a biologically meaningful parameter in carcinogenesis and potentially serve as novel prognostic biomarker in renal cell carcinoma (RCC). MATERIALS AND METHODS: In this retrospective analysis (n=652) we evaluated the potential prognostic value of MPV and its ability to improve existing risk assessment tools used in adjuvant clinical trials in non-metastatic RCC...
July 14, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28716439/renal-cell-carcinoma-unclassified-with-medullary-phenotype-poorly-differentiated-adenocarcinomas-overlapping-with-renal-medullary-carcinoma
#6
Deepika Sirohi, Steven C Smith, Chisato Ohe, Piergiuseppe Colombo, Mukul Divatia, Ema Dragoescu, Priya Rao, Michelle S Hirsch, Ying-Bei Chen, Rohit Mehra, Mahul B Amin
Renal medullary carcinoma (RMC) is a highly aggressive renal cell carcinoma, arising in the collecting system, and requiring careful correlation with status of sickle cell trait. A panel of international experts has recently proposed provisional diagnostic terminology, renal cell carcinoma, unclassified, with medullary phenotype (RCCU-MP), based on encountering an extraordinarily rare tumor with RMC morphology and immunophenotype in an individual proven not to have a hemoglobinopathy. Herein, we extend this observation to a cohort of five such tumors, morphologically similar to RMC, lacking SMARCB1 expression by immunohistochemistry, but each without evidence of a hemoglobinopathy...
July 14, 2017: Human Pathology
https://www.readbyqxmd.com/read/28710314/sarcomatoid-renal-cell-carcinoma-has-a-distinct-molecular-pathogenesis-driver-mutation-profile-and-transcriptional-landscape
#7
Zixing Wang, Tae Beom Kim, Bo Peng, Jose A Karam, Chad J Creighton, Aron Y Joon, Fumi Kawakami, Patricia Trevisan, Eric Jonasch, Chi-Wan Chow, Jaime Rodriguez-Canales, Pheroze Tamboli, Nizar M Tannir, Christopher G Wood, Federico A Monzon, Keith A Baggerly, Marileila Varella-Garcia, Bogdan Czerniak, Ignacio I Wistuba, Gordon B Mills, Kenna Shaw, Ken Chen, Kanishka Sircar
Sarcomatoid renal cell carcinoma (SRCC) ranks among the most aggressive clinicopathologic phenotypes of RCC. However, the paucity of high-quality, genome-wide molecular examinations of SRCC has hindered our understanding of this entity.<br /><br />Experimental Design: We interrogated the mutational, copy number, and transcriptional characteristics of SRCC and compared these data with those of non-sarcomatoid RCC (RCC). We evaluated whole exome sequencing, single nucleotide polymorphism, and RNA sequencing data from patients with SRCC (n=65) and RCC (n=598) across different parent RCC subtypes, including clear cell RCC, papillary RCC, and chromophobe RCC subtypes...
July 14, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28686500/guidelines-for-pathologic-diagnosis-of-malignant-mesothelioma-2017-update-of-the-consensus-statement-from-the-international-mesothelioma-interest-group
#8
Aliya Noor Husain, Thomas V Colby, Nelson G Ordóñez, Timothy Craig Allen, Richard Luther Attanoos, Mary Beth Beasley, Kelly Jo Butnor, Lucian R Chirieac, Andrew M Churg, Sanja Dacic, Françoise Galateau-Sallé, Allen Gibbs, Allen M Gown, Thomas Krausz, Leslie Anne Litzky, Alberto Marchevsky, Andrew G Nicholson, Victor Louis Roggli, Anupama K Sharma, William D Travis, Ann E Walts, Mark R Wick
CONTEXT: - Malignant mesothelioma (MM) is an uncommon tumor that can be difficult to diagnose. OBJECTIVE: - To provide updated, practical guidelines for the pathologic diagnosis of MM. DATA SOURCES: - Pathologists involved in the International Mesothelioma Interest Group and others with an interest and expertise in the field contributed to this update. Reference material included up-to-date, peer-reviewed publications and textbooks. CONCLUSIONS: - There was discussion and consensus opinion regarding guidelines for (1) distinguishing benign from malignant mesothelial proliferations (both epithelioid and spindle cell lesions), (2) cytologic diagnosis of MM, (3) recognition of the key histologic features of pleural and peritoneal MM, (4) use of histochemical and immunohistochemical stains in the diagnosis and differential diagnosis of MM, (5) differentiating epithelioid MM from various carcinomas (lung, breast, ovarian, and colonic adenocarcinomas, and squamous cell and renal cell carcinomas), (6) diagnosis of sarcomatoid MM, (7) use of molecular markers in the diagnosis of MM, (8) electron microscopy in the diagnosis of MM, and (9) some caveats and pitfalls in the diagnosis of MM...
July 7, 2017: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/28675457/metastatic-sarcomatoid-renal-cell-carcinoma-manifesting-as-a-subcutaneous-soft-tissue-mass
#9
Valentina Logunova, Olayemi Sokumbi, Kenneth A Iczkowski
Spindle cell lesions of the superficial soft tissues often pose a diagnostic challenge due to frequently non-specific clinico-radiologic presentation and overlapping microscopic features, therefore immunohistochemistry remains a favored approach in separating them.
July 4, 2017: Journal of Cutaneous Pathology
https://www.readbyqxmd.com/read/28673798/rapid-response-to-nivolumab-in-a-patient-with-sarcomatoid-transformation-of-chromophobe-renal-cell-carcinoma
#10
Keren Rouvinov, Lidia Osyntsov, Ruthy Shaco-Levy, Nina Baram, Samuel Ariad, Wilmosh Mermershtain
No abstract text is available yet for this article.
June 3, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28669641/prognostic-significance-of-extensive-necrosis-in-renal-cell-carcinoma
#11
Jennifer Collins, Jonathan I Epstein
Few studies using the current classification of renal cell carcinoma (RCC) have looked at a large number of cases with near total necrosis. We identified 21 cases of resections of RCC with >90% necrosis from the archives of Johns Hopkins Hospital between 2000-2015. Patients' mean age was 59yrs. (43-77) with 16 (76%) males. 12 (57%) cases were papillary RCC, 4 (19%) clear cell papillary RCC, 4 (19%) clear cell RCC, 1 (5%) unclassified with sarcomatoid differentiation. International Society of Urological Pathology (ISUP) nucleolar grade was grade 1 (9 cases) or grade 2 (9 cases)...
June 29, 2017: Human Pathology
https://www.readbyqxmd.com/read/28669254/papillary-renal-cell-carcinoma-with-osteosarcomatous-heterologous-differentiation-a-case-report-with-molecular-genetic-analysis-and-review-of-the-literature
#12
John James Aird, Aisling U Nic An Riogh, Stewart Fleming, R Gordon Hislop, Paul Sweeney, Nick Mayer
Sarcomatoid differentiation can occur in all subtypes of renal cell carcinoma (RCC). In rare cases, heterologous differentiation has been described. We present a case of heterologous osteosarcomatous differentiation in association with sarcomatoid papillary RCC including an analysis of chromosomal copy number alteration. This is the first case to identify heterologous differentiation in association with papillary RCC. The patient was a 70-year-old man who had a mass in the right kidney. Speckled calcification was seen on computed tomography scan...
June 1, 2017: International Journal of Surgical Pathology
https://www.readbyqxmd.com/read/28667776/preservation-of-truncal-genomic-alterations-in-clear-cell-and-papillary-renal-cell-carcinomas-with-sarcomatoid-features-an-intra-and-intertumoral-multifocal-fluorescence-in-situ-hybridization-analysis-reveals-limited-genetic-heterogeneity
#13
Joseph M Sanfrancesco, John N Eble, David J Grignon, Mingsheng Wang, Shaobo Zhang, Chandru P Sundaram, Muhammad T Idrees, Roberto Pili, Erik Kouba, Liang Cheng
Understanding tumor genomic heterogeneity may offer vital information in an age of targeted therapy for renal cell carcinoma. We sought to investigate hallmark truncal chromosomal alterations between conventional, sarcomatoid, and matched metastatic tumor foci in clear cell and papillary renal cell carcinomas. A retrospective review identified 58 cases including clear cell (CCRCC) and papillary renal cell carcinomas (PRCC). All cases contained sarcomatoid transformation. Additionally, 10 of 58 patients had matched metastatic disease available for analysis...
July 1, 2017: Molecular Carcinogenesis
https://www.readbyqxmd.com/read/28651491/manifestation-of-osteoblastic-phenotypes-in-the-sarcomatous-component-of-epithelial-carcinoma-and-sarcomatoid-carcinoma
#14
Yasutoshi Takashima, Teppei Murakami, Takao Inoue, Man Hagiyama, Azusa Yoneshige, Syunji Nishimura, Masao Akagi, Akihiko Ito
Epithelial carcinomas occasionally have sarcomatous components that consist primarily of spindle and cuboidal cells, which often resemble osteoblasts. Sarcomatoid carcinomas consist of similar cells. Recent studies have characterized these phenomena as a manifestation of epithelial-mesenchymal transition in carcinoma cells, but the mesenchymal phenotypes that manifest in sarcomatous cells of epithelial carcinomas are not well understood. Here, we examined the expression profiles of four osteoblastic differentiation biomarkers in the sarcomatous components of multiple carcinoma types, including five renal clear cell, four breast invasive ductal, two esophageal, one maxillary squamous cell, three larynx, three lung, one liver, and one skin sarcomatoid carcinoma...
June 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28645484/immune-check-point-inhibition-in-sarcomatoid-renal-cell-carcinoma-a-new-treatment-paradigm
#15
Ruben Raychaudhuri, Matthew J Riese, Kathryn Bylow, John Burfeind, Alexander C Mackinnon, Parag P Tolat, Kenneth A Iczkowski, Deepak Kilari
No abstract text is available yet for this article.
May 25, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28620133/the-pvhl172-isoform-is-not-a-tumor-suppressor-and-up-regulates-a-subset-of-pro-tumorigenic-genes-including-tgfb1-and-mmp13
#16
P Hascoet, F Chesnel, F Jouan, C Le Goff, A Couturier, E Darrigrand, F Mahé, N Rioux-Leclercq, X Le Goff, Y Arlot-Bonnemains
The von Hippel-Lindau (VHL) tumor suppressor gene is often deleted or mutated in ccRCC (clear cell renal cell carcinoma) producing a non-functional protein. The gene encodes two mRNA, and three protein isoforms (pVHL213, pVHL160 and pVHL172). The pVHL protein is part of an E3 ligase complex involved in the ubiquitination and proteasomal degradation of different proteins, particularly hypoxia inducible factors (HIF) that drive the transcription of genes involved in the regulation of cell proliferation, angiogenesis or extracellular matrix remodelling...
June 6, 2017: Oncotarget
https://www.readbyqxmd.com/read/28561708/systemic-therapy-for-non-clear-cell-renal-cell-carcinoma
#17
Tian Zhang, Jun Gong, Manuel Caitano Maia, Sumanta K Pal
Treatment options for metastatic clear cell renal cell carcinoma (ccRCC) have evolved markedly over the past decade, with multiple targeted therapies approved for the disease. In contrast, little improvement has been made in the management of metastatic non-clear cell RCC (nccRCC). Non-clear cell disease is an umbrella term that encompasses multiple biologically distinct entities, including but not limited to papillary, chromophobe, and sarcomatoid RCC. To date, prospective studies have largely explored treatments for ccRCC (e...
2017: American Society of Clinical Oncology Educational Book
https://www.readbyqxmd.com/read/28552571/prognostic-factors-for-survival-of-patients-with-synchronous-or-metachronous-brain-metastasis-of-renal-cell-carcinoma
#18
Se Young Choi, Sangjun Yoo, Dalsan You, In Gab Jeong, Cheryn Song, Bumsik Hong, Jun Hyuk Hong, Hanjong Ahn, Choung-Soo Kim
INTRODUCTION: We evaluated the oncological outcomes of synchronous or metachronous brain metastasis (BM) of metastatic renal cell carcinoma (RCC) according to clinicopathologic factors. PATIENTS AND METHODS: Patients with metastatic RCC (n = 93) with synchronous and metachronous BM were retrospectively identified. We analyzed patients and tumor characteristics, treatment methods, prognostic factors, BM progression, and overall survival (OS). RESULTS: Seventy-six patients (81...
May 10, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28550387/correlation-of-c-met-expression-with-pd-l1-expression-in-metastatic-clear-cell-renal-cell-carcinoma-treated-by-sunitinib-first-line-therapy
#19
Solène-Florence Kammerer-Jacquet, Sarah Medane, Karim Bensalah, Jean-Christophe Bernhard, Mokrane Yacoub, Frantz Dupuis, Alain Ravaud, Grégory Verhoest, Romain Mathieu, Benoit Peyronnet, Angélique Brunot, Brigitte Laguerre, Alexandra Lespagnol, Jean Mosser, Frédéric Dugay, Marc-Antoine Belaud-Rotureau, Nathalie Rioux-Leclercq
BACKGROUND: Clear cell renal cell carcinoma (ccRCC) is highly metastatic. Cabozantinib, an anti-angiogenic tyrosine kinase inhibitor that targets c-MET, provided interesting results in metastatic ccRCC treatment. OBJECTIVE: To understand better the role of c-MET in ccRCC, we assessed its status in a population of patients with metastatic ccRCC. PATIENTS AND METHODS: For this purpose, tumor samples were analyzed for c-MET expression by immunohistochemistry (IHC), for c-MET copy number alterations by fluorescence in situ hybridization (FISH), and for c-MET mutations by next generation sequencing (NGS) in a retrospective cohort of 90 primary ccRCC of patients with metastases treated by first-line sunitinib...
August 2017: Targeted Oncology
https://www.readbyqxmd.com/read/28546525/pazopanib-for-the-treatment-of-non-clear-cell-renal-cell-carcinoma-a-single-arm-open-label-multicenter-phase-ii-study
#20
Ki Sun Jung, Su Jin Lee, Se Hoon Park, Jae-Lyun Lee, Se-Hoon Lee, Jae Yun Lim, Jung Hun Kang, Suee Lee, Sun Young Rha, Kyung Hee Lee, Ho Young Kim, Ho Yeong Lim
Purpose: The optimal treatment strategy for patients with metastatic non-clear cell type renal cell carcinoma (nccRCC) remains unclear. Although several inhibitors of vascular endothelial growth factor have recently shown efficacy against nccRCC, the clinical benefit of pazopanib in nccRCC has not been analyzed. We therefore designed a single-arm, open-label, phase II study to determine the efficacy and safety of pazopanib in patients with nccRCC. Materials and Methods: Patients with locally advanced or metastatic nccRCC, except for collecting duct or sarcomatoid type, received 800mg/day of pazopanib daily until progression of disease or intolerable toxicity...
May 22, 2017: Cancer Research and Treatment: Official Journal of Korean Cancer Association
keyword
keyword
51054
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"